FDA, Merck, and Vioxx putting patient safety first? : hearing before the Committee on Finance, United States Senate, One Hundred Eighth Congress, second session, November 18, 2004.

Saved in:

Bibliographic Details
Corporate author / creator:	United States. Congress. Senate. Committee on Finance.
Imprint:	Washington : U.S. G.P.O., 2005.
Description:	iv, 921 p. : ill. ;
Language:	English
Series:	S. hrg. ; 108-791 United States. Congress. Senate. S. hrg. ; 109-791.
Subject:	Merck & Co. -- Corrupt practices. Rofecoxib. Drug monitoring -- United States. Drugs -- United States -- Testing.
Format:	E-Resource U.S. Federal Government Document Book
URL for this record:	http://pi.lib.uchicago.edu/1001/cat/bib/10732500

Hidden Bibliographic Details
Other uniform titles:	ProQuest U.S. Congressional Hearings Digital Collection.
Notes:	This document has been withdrawn from the federal depository library program at the request of the publishing agency on 6/20/06. Reuse of record except for individual research requires license from ProQuest, LLC. Includes bibliographical references. Statements of committee chairs and testimony of expert witnesses also available via Internet from the GPO permanent archive. Address as of 10/25/06: http://permanent.access.gpo.gov/lps75299/merckvioxx.pdf; current access available via PURL.
Other form:	Print version: United States.Congress.Senate.Committee on Finance. FDA, Merck, and Vioxx Microfiche version: United States.Congress.Senate.Committee on Finance. FDA, Merck, and Vioxx [Bethesda, Md.] : ProQuest LLC, [2004] CIS 2006 S361-19

Similar Items